Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | STAMBP | O95630 | 1/20 | 0.43 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.42 |
| ▸ | GRK2 | P25098 | 5/20 | 0.42 |
| ▸ | PRKCA | P17252 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | GRK5 | P34947 | 1/20 | 0.41 |
| ▸ | GRK3 | P35626 | 1/20 | 0.41 |
| ▸ | GRK7 | Q8WTQ7 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6846603 | 0.84 | SLC29A1 (0.47) | PARP1MAPK1ROCK2ALDH1A1MAPT | |
| SCHEMBL6844806 | 0.82 | GAA (0.50) | MAPK1ROCK2GRK2PRKCAALDH1A1 | |
| SCHEMBL7229294 | 0.81 | ALDH1A1 (0.43) | LMNAPARP1MAPK1ROCK2ALDH1A1 | |
| SCHEMBL6846844 | 0.79 | MAPT (0.47) | LMNAMAPK1ALDH1A1MAPTCYP1A2 | |
| SCHEMBL6845380 | 0.78 | ALDH1A1 (0.49) | MAPK1ALDH1A1MAPTPOLBRAB9A | |
| SCHEMBL7592061 | 0.78 | ALDH1A1 (0.48) | MAPK1ROCK2ALDH1A1MAPTROCK1 | |
| SCHEMBL6846677 | 0.77 | ALDH1A1 (0.48) | LMNAPARP1MAPK1ALDH1A1MAPT | |
| SCHEMBL6846651 | 0.77 | ALDH1A1 (0.48) | LMNAPARP1MAPK1ALDH1A1MAPT | |
| SCHEMBL6846427 | 0.77 | NPC1 (0.50) | LMNATSHRMAPK1ALDH1A1MAPT | |
| SCHEMBL6841325 | 0.77 | FLT3 (0.50) | MAPK1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | claimed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | claimed |
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | LMNA 4001/4885TSHR 2259/4885PARP1 2139/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | LMNA 4001/4885TSHR 2259/4885PARP1 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.